Seasonal flu vaccine effectiveness in the United States has ranged from about 10% to 60% over the past two decades, depending on the year, with most seasons landing somewhere between 30% and 50%. Those numbers sound underwhelming compared to, say, the measles vaccine, and they are a genuine source of confusion for people trying to decide whether the shot is worth the trip to the pharmacy. But the headline effectiveness figure measures only one thing, and the picture changes when you look at what the vaccine does against hospitalization, intensive care, and death.
What the Year-to-Year Numbers Actually Look Like
The CDC’s Flu Vaccine Effectiveness Network has tracked how well the flu shot prevents medically attended influenza illness every season since the mid-2000s. The overall effectiveness estimates tell a choppy story. In some seasons the vaccine cut the risk of needing to see a doctor for the flu by more than half. In others, it barely made a dent. A few highlights from the data: 2010–11 saw effectiveness of about 60%, while 2014–15 was a dismal 19%. More recently, 2023–24 came in at 44%, and the preliminary 2024–25 estimate was 56%.{1CDC Seasonal Flu Vaccine Effectiveness Studies. CDC Seasonal Flu Vaccine Effectiveness Studies
If you average things out across many seasons, somewhere around 40% is a reasonable ballpark for overall effectiveness against lab-confirmed flu illness in outpatient settings. That means a vaccinated person is roughly 40% less likely to wind up at a doctor’s office or urgent care clinic with flu than an unvaccinated person. It does not mean 60% of vaccinated people get the flu. The number describes a relative risk reduction, not a failure rate.
Why the Numbers Swing So Wildly From Year to Year
Flu is not one virus. It is a shifting collection of influenza A and B subtypes, and the dominant strain matters enormously for how well the vaccine works in any given season. Over the decade from 2010 to 2020, the vaccine’s track record against A(H1N1) and influenza B was considerably better than against A(H3N2). H3N2 seasons often dragged overall effectiveness estimates below 40%, and in two of the seven seasons where H3N2-specific estimates were available, the confidence intervals suggested the vaccine provided no statistically significant protection at all.2Clinical Infectious Diseases. Influenza During the 2010–2020 Decade in the United States: Seasonal Outbreaks and Vaccine Interventions
Influenza B has generally been easier to vaccinate against. Over four seasons of data from the US Flu VE Network, quadrivalent vaccine effectiveness against influenza B ranged from about 48% to 85%, with higher effectiveness in younger children and against the B/Victoria lineage.3Open Forum Infectious Diseases. P-712. Effectiveness of Seasonal Influenza Vaccines against Medically Attended Influenza B, US Flu VE Network
Vaccine scientists have to pick which strains to include in each year’s formulation months before flu season starts, using predictions about which viruses will circulate. When the match is poor, effectiveness drops. But even a mismatch does not zero out protection entirely. A systematic review and meta-analysis of randomized trials found that both inactivated and live-attenuated flu vaccines retained meaningful, if reduced, effectiveness against mismatched strains. In adults, the inactivated vaccine had about 52% effectiveness against mismatched strains compared to 65% against matched ones.4PubMed Central. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis
How Growing Vaccines in Eggs Can Weaken Them
Most flu vaccines worldwide are still grown in chicken eggs. The virus sometimes picks up mutations as it adapts to growing in avian cells, and those mutations can change the parts of the virus that your immune system learns to recognize. The result is a subtle but real mismatch between the vaccine virus and the actual circulating strain, even when the “correct” strain was chosen for the vaccine. This is called egg adaptation, and it has been a persistent headache for H3N2 in particular.5PubMed. The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness
An expert consensus estimated that egg-adaptation mutations reduce vaccine effectiveness by roughly 4–16%, with the biggest hit falling on H3N2 in people under 65.6PubMed Central. Estimation of Reduction in Influenza Vaccine Effectiveness Due to Egg-Adaptation Changes—Systematic Literature Review and Expert Consensus Which specific mutations emerge depends on the genetic background of the circulating strain, so the severity of the egg-adaptation problem varies from year to year.7PLOS Pathogens. Egg-adaptive mutations of human influenza H3N2 virus are contingent on natural evolution
Cell-based and recombinant vaccines were developed partly to dodge this issue. In theory, growing the virus in mammalian cells or skipping the virus entirely (as recombinant vaccines do) should eliminate egg-adaptation mutations and produce a better match. In practice, the real-world advantage has been hard to pin down. A study of the 2022–23 season in adults aged 18–64 found that cell-based and egg-based vaccines provided comparable protection against hospitalization.8PubMed Central. Comparative Effectiveness of Cell‐Based Versus Egg‐Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022–2023 Season Among Adults 18–64 Years A randomized trial comparing recombinant to egg-based vaccine in adults found a relative advantage of about 29% for recombinant, but the confidence interval was wide enough to include the possibility of no benefit.9Open Forum Infectious Diseases. Relative Effectiveness and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Versus Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18–64 Years A cluster-randomized trial in nursing homes found nearly identical hospitalization and death rates between recombinant and standard egg-based vaccine groups.10JAMA Network Open. Recombinant vs Egg-Based Quadrivalent Influenza Vaccination for Nursing Home Residents: A Cluster Randomized Trial The promise of non-egg-based vaccines is real, but the evidence so far has not shown a consistent, dramatic edge in the populations studied.
Protection Against Severe Illness Is the Bigger Story
The headline effectiveness numbers measure protection against any medically attended flu illness, meaning you felt sick enough to go see someone. But most people’s real fear is being hospitalized, landing in intensive care, or dying. Here the vaccine performs better than its outpatient numbers suggest.
During the 2023–24 season, the flu shot was about 58% effective against hospitalization and emergency department visits in children and adolescents, and about 39% effective against hospitalization in adults.11Clinical Infectious Diseases. Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States A large meta-analysis pooling data across many seasons found the vaccine was about 42% effective against flu-related hospitalization, roughly 52% effective at keeping people out of the ICU, and about 55% effective at preventing the need for a ventilator.12PubMed. Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta-analysis of test-negative design studies A Spanish study over six flu seasons found that vaccination was associated with a 23% reduction in the combined risk of ICU admission or death among hospitalized flu patients.13PubMed Central. Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16
In other words, even in seasons when the vaccine is mediocre at preventing a trip to the doctor, it still meaningfully reduces your chances of ending up in a hospital bed. The protection is not perfect, but it is consistently in the direction of less-severe illness when breakthrough infections happen.
The Flu Shot and Children
Children benefit from the flu vaccine at least as much as adults, and the data on preventing pediatric deaths is particularly striking. An analysis of flu-associated pediatric deaths reported in the United States from 2016 through 2025 found that vaccination was 80% effective at preventing fatal influenza in children aged 6 months to 17 years. Among children without underlying health conditions, the estimate was even higher, at 87%.14Pediatrics. Influenza Vaccine Effectiveness Against Pediatric Death in the United States: 2016–2025 An earlier analysis covering 2010–2014 found 65% effectiveness against pediatric flu death overall, and 51% in children with high-risk medical conditions.15Pediatrics. Influenza Vaccine Effectiveness Against Pediatric Deaths: 2010–2014
These numbers are substantially higher than the effectiveness against outpatient illness, and they represent an outcome where even partial protection carries enormous weight. A vaccine that is 40% effective at keeping a child from getting the flu at all but 80% effective at preventing death from the flu is doing more than the headline number captures.
Vaccinating During Pregnancy Protects Newborns
Babies under six months are too young to be vaccinated themselves, but they can inherit flu-fighting antibodies from their mothers. A study of pregnant women who received the flu shot found it was about 63% effective at preventing lab-confirmed influenza in their infants, and respiratory illness with fever dropped by roughly 29% among those babies.16PubMed. Effectiveness of maternal influenza immunization in mothers and infants Another study estimated that maternal vaccination was over 90% effective at preventing flu-related hospitalization in infants under six months.17PubMed Central. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants
Timing matters. Babies born to mothers vaccinated in the second or third trimester had significantly higher levels of flu-specific antibodies in their cord blood compared to babies born to unvaccinated mothers.18PubMed Central. The impact of timing of maternal influenza immunization on infant antibody levels at birth Those transferred antibodies serve as a shield during the window when the infant cannot yet build its own vaccine response.
Protection Fades Over the Course of a Season
Flu vaccine immunity is not like a light switch that stays on for exactly six months. Antibody levels tend to peak about a month after vaccination and then decline gradually. A systematic review confirmed this pattern: a rise at one month followed by a drop at six months post-vaccination.19PubMed. Intraseasonal waning immunity of seasonal influenza vaccine – A systematic review and meta-analysis Modeling work has estimated that measured vaccine effectiveness drops by a few percentage points per month, with the rate depending on the virus type and how intense the flu season is. For a moderate-intensity season, the decline was estimated at roughly 2% per month for H1N1 and about 1% per month for H3N2 and influenza B.20PubMed Central. Waning of Measured Influenza Vaccine Effectiveness Over Time: The Potential Contribution of Leaky Vaccine Effect
This waning is why public health guidance generally recommends getting vaccinated in September or October rather than in August. Getting it too early risks having faded protection by the time flu activity peaks in January or February. Getting it too late risks missing early-season illness. There is no perfect window, but early fall is a reasonable compromise for most people.
Does Getting the Shot Every Year Dull Your Response?
This is one of the more uncomfortable questions in flu vaccinology. A systematic review and meta-analysis found that people vaccinated in consecutive seasons did have somewhat lower protection compared to people vaccinated only in the current season. The drop was most pronounced for H3N2, where consecutive vaccination was associated with about 18 percentage points less effectiveness, and smaller for H1N1 (about 9 points) and influenza B (about 7 points).21PubMed Central. Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis However, that same meta-analysis found that vaccination in both seasons still provided better protection than no vaccination at all. Getting the shot annually is still better than skipping years, even if the marginal boost from each successive year may be smaller.
A study of healthcare workers offered a mechanistic window into why this happens: repeated vaccination with the same virus strains increased antibody persistence but dampened the fresh antibody response to subsequent doses. Updating the vaccine viruses appeared to partially restore the response.22npj Vaccines. Effects of repeated influenza vaccination and infection on durable seroprotection in healthcare workers This phenomenon is tangled up with a concept called immunological imprinting: your immune system’s first encounter with a flu virus shapes how it responds to all subsequent flu encounters. Early-life exposure can create a template that biases your immune response toward the strain you first met, sometimes at the expense of responding optimally to newer ones.23PubMed Central. Influenza Vaccines Delivered in Early Childhood Could Turn Antigenic Sin into Antigenic Blessings Some researchers see this as a potential lever: if you could shape that first imprint through vaccination before a child’s first natural infection, you might set up a broader, more durable immune foundation.24PubMed Central. From Original Antigenic Sin to the Universal Influenza Virus Vaccine
Cardiovascular Benefits Beyond the Lungs
One of the more surprising findings in flu vaccine research is its apparent effect on heart attacks and strokes. A meta-analysis of clinical trials found that flu vaccination was associated with a roughly 30% reduction in major cardiovascular events among people at high risk, with an absolute risk difference meaning that about 58 people needed to be vaccinated to prevent one major event within a year.25JAMA. Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients: A Meta-analysis A more recent meta-analysis also found a significant reduction in cardiovascular risk among vaccinated patients.26PubMed Central. Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies
In elderly populations, vaccination has been linked to reduced hospitalizations for cardiac disease by about 19% and for stroke by 16–23% across two flu seasons.27PubMed. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly The mechanism is thought to involve the systemic inflammation that a flu infection triggers, which can destabilize arterial plaques and increase clotting risk. Preventing the infection, or at least softening its severity, appears to reduce that cardiovascular cascade.
Herd Protection and the Limits of Individual Data
When enough people in a community are vaccinated, unvaccinated individuals also benefit because the virus has fewer hosts to spread through. Modeling for Germany estimated that vaccinating children aged 2–17 at rates of 20–60% would prevent four to seven times as many cases among unvaccinated people as among the vaccinated children themselves. For outcomes like flu-related death, which disproportionately affect unvaccinated elderly adults, the indirect benefit could exceed the direct benefit by a factor of 20 or more.28PubMed Central. Direct and indirect effects of influenza vaccination
Real-world evidence for this herd effect has been harder to nail down. An eight-year household cohort study in the US found little evidence of indirect protection after adjusting for confounders: unvaccinated people in partly vaccinated households were not significantly less likely to get flu than unvaccinated people in fully unvaccinated households.29Clinical Infectious Diseases. Effectiveness of Influenza Vaccines in the HIVE Household Cohort Over 8 Years: Is There Evidence of Indirect Protection? The disconnect between the modeling and the household data likely reflects that current vaccination coverage is too patchy and vaccine effectiveness too variable to generate a strong, measurable herd effect at the household level.
Is the Flu Shot Cost-Effective?
Flu vaccination consistently falls within the range of cost-effectiveness that health systems consider worthwhile. For adults 65 and older, the vaccine is often cost-saving, meaning it prevents enough hospitalizations and medical costs to more than pay for itself. For working-age adults between 18 and 64, estimates ranged from about $8,000 to $39,000 per quality-adjusted life year gained, which compares favorably to other widely accepted preventive measures like breast cancer screening or colorectal cancer screening.30PubMed Central. A review of the cost-effectiveness of adult influenza vaccination and other preventive services A separate analysis found that vaccination remained cost-effective for older adults even at vaccine effectiveness estimates as low as 4%.31PubMed. Cost-effectiveness of routine annual influenza vaccination by age and risk status For younger, healthy adults without risk factors, the economic case is weaker, though workplace absenteeism and productivity losses are harder to capture in formal models.
Nasal Spray Versus the Needle
The live-attenuated nasal spray vaccine works differently from the standard injected shot. The spray delivers a weakened live virus to the lining of the nose, prompting a local immune response, while the injected version uses killed virus to generate a systemic antibody response. In children, the two approaches stimulate distinct immune profiles. The injected vaccine is better at boosting circulating memory immune cells, while the nasal spray generates a mucosal response that the shot does not.32PubMed Central. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines
A systematic review and meta-analysis comparing the two in children found no overall significant difference in efficacy between the quadrivalent nasal spray and the standard injected vaccine. However, when looking at larger multi-center trials specifically, the trivalent nasal spray was superior to the trivalent injected vaccine in children.33PubMed Central. Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis For adults, the nasal spray generally performs less well than the injected vaccine, and it is not recommended for people over 50 or those with weakened immune systems.
The Search for a Universal Flu Vaccine
The annual guessing game of which strains to include is the single biggest limitation of current flu vaccines. Several research programs are trying to develop vaccines that target parts of the influenza virus that do not change much from year to year, which would eliminate the need for a new formulation each season. One leading approach uses chimeric constructs that combine unusual head portions of the virus’s surface protein with a conserved stalk region, training the immune system to focus on the stable part rather than the highly variable part. Other candidates target different conserved viral proteins altogether. A phase 2 trial of one such candidate, called FLU-v, found it was immunogenic with adjuvant and was recommended for further development.34PubMed. Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial None of these candidates have reached the market yet, and the timeline to a truly universal flu vaccine remains uncertain. But the science is no longer theoretical: multiple approaches are in clinical trials, and the problem of strain-matching could eventually become a thing of the past.